Targeting glutamine metabolism in myeloproliferative neoplasms
H Zhan, K Ciano, K Dong, S Zucker - Blood Cells, Molecules, and Diseases, 2015 - Elsevier
Abstract JAK2 V617F mutation can be detected in the majority of myeloproliferative
neoplasm (MPN) patients. The JAK2 inhibitor Ruxolitinib is the first FDA-approved treatment
for MPNs. However, its use is limited by various dose related toxicities. Here, we studied the
metabolic state and glutamine metabolism of BaF3-hEPOR-JAK2V617F and BaF3-hEPOR-
JAK2WT cells. We found that the JAK2 V617F-mutant cells were associated with increased
oxygen consumption rate and extracellular acidification rate than the JAK2 WT cells and …
neoplasm (MPN) patients. The JAK2 inhibitor Ruxolitinib is the first FDA-approved treatment
for MPNs. However, its use is limited by various dose related toxicities. Here, we studied the
metabolic state and glutamine metabolism of BaF3-hEPOR-JAK2V617F and BaF3-hEPOR-
JAK2WT cells. We found that the JAK2 V617F-mutant cells were associated with increased
oxygen consumption rate and extracellular acidification rate than the JAK2 WT cells and …